POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Severe Neutropenia (Grade 4 Neutropenia) as a Population Based Predictor for Adverse Clinical Outcome of Chemotherapy Induced Neutropenia
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Impact of Adding Plinabulin to Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia on Patient Quality of Life (QoL)
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Prediction of Febrile Neutropenia , Hospitalization Rates, and Infection Rates in Chemotherapy-Induced Neutropenia Patients Treated with the Plinabulin and Pegfilgrastim Combination (Plin+Peg) using a Meta-Analysis -based Tool
Federation of Clinical Immunology Societies (FOCIS) 2021
06.2021
Federation of Clinical Immunology Societies (FOCIS) 2021
Adding Plinabulin (Plin) to Pegfilgrastim (Peg) Reverses the Immune Suppressive Potential of Peg while Offering Superior Prevention of Chemotherapy Induced Neutropenia (CIN) versus Peg Alone
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Combination Plinabulin+Pegfilgrastim (Plin+Peg) Had Better Toxicity Management and Health Related Quality-of-Life (HrQoL) Compared to Peg Alone in Early-stage Breast Cancer (BC) Patients (pts) Treated With Taxotere, Doxorubicin and Cyclophosphamide (TAC)
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Mechanistic evidence associated with the benefit of plinabulin significantly reducing bone pain in breast cancer patients (pts)
treated with TAC (Docetaxel, Doxorubicin, Cyclophosphamide) and Pegfilgrastim (Peg)
PUBLICATIONS
Chem
11.14.2019
Chem
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes
Cell Reports
09.24.2019
Cell Reports
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-Tumor Responses
Investigational New Drugs
02.16.2011
Investigational New Drugs
Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel
Clinical Cancer Research (2010) 16:5892-5899
12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
JAMA Oncology 2020
09.24.2020
JAMA Oncology
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies